{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T18:45:20Z","timestamp":1779129920229,"version":"3.51.4"},"reference-count":62,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>With recent advances in genetic sequencing and its widespread adoption for clinical diagnostics, the identification of a primary immunodeficiency (PID) as the underlying cause of diseases presenting to hematologists including refractory autoimmunity, cytopenias, immune dysregulation, and hematologic malignancy, is increasing, particularly in the adult population. Where the pathogenic genetic variants are restricted to the hematopoietic system, selected patients may benefit from allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although it is generally accepted that early allo-HSCT (ie, in infancy or childhood) for PID is preferable, this is not always possible. The clinical phenotype of non\u2013severe combined immune deficiency forms of PID can be very heterogeneous, in part because of the high number of genetic and functional defects affecting T, B, and natural killer cells, neutrophils, and\/or antigen presentation. As a result, some patients have less severe disease manifestations in childhood and\/or a later de novo presentation. For others, a delayed diagnosis, lack of a genetic diagnosis, or a previous lack of a suitable donor has precluded prior allo-HSCT. Specific issues which make transplantation for adult PID patients particularly challenging are discussed, including understanding the natural history of rare diseases and predicting outcome with conservative management alone; indications for and optimal timing of transplant; donor selection; conditioning regimens; and PID-specific transplant management. The role of gene therapy approaches as an alternative to allo-HSCT in high-risk monogenic PID is also discussed.<\/jats:p>","DOI":"10.1182\/hematology.2020000152","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T04:04:59Z","timestamp":1607141099000},"page":"649-660","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency"],"prefix":"10.1182","volume":"2020","author":[{"given":"Emma C.","family":"Morris","sequence":"first","affiliation":[{"name":"Institute of Immunity and Transplantation, University College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"1","key":"2020121621270861200_B1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s10875-020-00758-x","article-title":"Human inborn errors of immunity: 2019 update of the IUIS Phenotypical Classification","volume":"40","author":"Bousfiha","year":"2020","journal-title":"J Clin Immunol"},{"issue":"7","key":"2020121621270861200_B2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1586\/1744666X.2016.1150177","article-title":"Stem cell transplantation for the treatment of immunodeficiency in children: current status and hopes for the future","volume":"12","author":"Booth","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"2020121621270861200_B3","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jaip.2016.09.004","article-title":"Primary immune deficiencies in the adult: a previously underrecognized common condition","volume":"4","author":"Rosenberg","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"2020121621270861200_B4","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jaip.2017.07.045","article-title":"Allogeneic stem cell transplantation in adolescents and young adults with primary immunodeficiencies","volume":"6","author":"Albert","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"2020121621270861200_B5","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1182\/blood-2017-09-807487","article-title":"Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency","volume":"131","author":"Fox","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2020121621270861200_B6","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2010-11-319376","article-title":"Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study","volume":"118","author":"Moratto","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2020121621270861200_B7","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.jaci.2018.12.1010","article-title":"Hematopoietic stem cell transplantation for CD40 ligand deficiency: results from an EBMT\/ESID-IEWP-SCETIDE-PIDTC study","volume":"143","author":"Ferrua","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"2020121621270861200_B8","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood-2018-09-876284","article-title":"The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases","volume":"133","author":"Thakar","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2020121621270861200_B9","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jaci.2016.07.040","article-title":"A prospective study on the natural history of patients with profound combined immunodeficiency: An interim analysis","volume":"139","author":"Speckmann","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"2020121621270861200_B10","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood-2011-09-377945","article-title":"Morbidity and mortality in common variable immune deficiency over 4 decades","volume":"119","author":"Resnick","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2020121621270861200_B11","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jaci.2014.11.029","article-title":"Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency","volume":"135","author":"Wehr","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"2020121621270861200_B12","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/cid\/ciw837","article-title":"Chronic granulomatous disease in patients reaching adulthood: a nationwide study in France","volume":"64","author":"Dunogu\u00e9","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020121621270861200_B13","article-title":"Long-term outcomes for adults with chronic granulomatous disease (CGD) in the United Kingdom (UK) [published ahead of print 21 September 2020]","author":"Campos","journal-title":"J Allergy Clin Immunol."},{"issue":"5","key":"2020121621270861200_B14","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2010-07-298372","article-title":"Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1\/SAP deficiency) versus type 2 (XLP-2\/XIAP deficiency)","volume":"117","author":"Pachlopnik Schmid","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2020121621270861200_B15","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaci.2016.07.039","article-title":"Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation","volume":"139","author":"de la Morena","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2020121621270861200_B16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10875-014-0126-0","article-title":"DOCK8 deficiency: clinical and immunological phenotype and treatment options: a review of 136 patients","volume":"35","author":"Aydin","year":"2015","journal-title":"J Clin Immunol"},{"key":"2020121621270861200_B17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3389\/fped.2019.00437","article-title":"Allogeneic HSCT in adolescents and young adults with primary immunodeficiencies","volume":"7","author":"Morris","year":"2019","journal-title":"Front Pediatr"},{"issue":"1","key":"2020121621270861200_B18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13023-017-0753-7","article-title":"Primary hemophagocytic lymphohistiocytosis in adults: the utility of family surveys in a single-center study from China","volume":"13","author":"Jin","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2020121621270861200_B19","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaci.2017.03.049","article-title":"Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations","volume":"141","author":"Leiding","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"2020121621270861200_B20","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s10875-017-0422-6","article-title":"Allogeneic reduced-intensity hematopoietic stem cell transplantation for chronic granulomatous disease: a single-center prospective trial","volume":"37","author":"Parta","year":"2017","journal-title":"J Clin Immunol"},{"issue":"6","key":"2020121621270861200_B21","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.bbmt.2017.03.016","article-title":"Haploidentical related donor hematopoietic stem cell transplantation for dedicator-of-cytokinesis 8 deficiency using post-transplantation cyclophosphamide","volume":"23","author":"Shah","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2020121621270861200_B22","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s12185-016-2062-7","article-title":"Allogeneic hematopoietic stem-cell transplantation for adult and adolescent hemophagocytic lymphohistiocytosis: a single center analysis","volume":"104","author":"Fu","year":"2016","journal-title":"Int J Hematol"},{"issue":"12","key":"2020121621270861200_B23","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.bbmt.2014.08.004","article-title":"Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency","volume":"20","author":"Grossman","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9915","key":"2020121621270861200_B24","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(13)62069-3","article-title":"Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study","volume":"383","author":"G\u00fcng\u00f6r","year":"2014","journal-title":"Lancet"},{"key":"2020121621270861200_B25","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1182\/blood-2013-07-515528","article-title":"GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity","volume":"123","author":"Spinner","year":"2014","journal-title":"Blood."},{"issue":"5","key":"2020121621270861200_B26","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1056\/NEJMoa1401177","article-title":"Transplantation outcomes for severe combined immunodeficiency, 2000-2009","volume":"371","author":"Pai","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"2020121621270861200_B27","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1586\/1744666X.2013.836061","article-title":"Advances in hematopoietic stem cell transplantation for primary immunodeficiency","volume":"9","author":"Slatter","year":"2013","journal-title":"Expert Rev Clin Immunol"},{"issue":"10","key":"2020121621270861200_B28","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/INF.0000000000000840","article-title":"Chronic granulomatous disease. A large, single-centre US experience","volume":"34","author":"Bortoletto","year":"2015","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"2020121621270861200_B29","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJM199902183400703","article-title":"Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency","volume":"340","author":"Buckley","year":"1999","journal-title":"N Engl J Med."},{"issue":"6","key":"2020121621270861200_B30","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10875-016-0306-1","article-title":"NF-\u03baB1 haploinsufficiency causing immunodeficiency and EBV-driven lymphoproliferation","volume":"36","author":"Boztug","year":"2016","journal-title":"J Clin Immunol"},{"issue":"1","key":"2020121621270861200_B31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10875-015-0224-7","article-title":"Spectrum of phenotypes associated with mutations in LRBA","volume":"36","author":"Alkhairy","year":"2016","journal-title":"J Clin Immunol"},{"issue":"1","key":"2020121621270861200_B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cei.12997","article-title":"Immune deficiency and autoimmunity in patients with CTLA-4 (CD152) mutations","volume":"190","author":"Verma","year":"2017","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"2020121621270861200_B33","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.jaci.2018.02.007","article-title":"Prevalence and clinical challenges among adults with primary immunodeficiency and recombination-activating gene deficiency","volume":"141","author":"Lawless","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"2020121621270861200_B34","doi-asserted-by":"crossref","first-page":"e478","DOI":"10.3324\/haematol.2018.215285","article-title":"T-cell replete haploidentical bone marrow transplantation and post-transplant cyclophosphamide for patients with inborn errors","volume":"104","author":"Kurzay","year":"2019","journal-title":"Haematologica"},{"key":"2020121621270861200_B35","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3389\/fped.2019.00434","article-title":"Conditioning perspectives for primary immunodeficiency stem cell transplants","volume":"7","author":"Shaw","year":"2019","journal-title":"Front Pediatr"},{"issue":"2","key":"2020121621270861200_B36","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/cpt.1715","article-title":"Proposed therapeutic range of treosulfan in reduced toxicity pediatric allogeneic hematopoietic stem cell transplant conditioning: results from a prospective trial","volume":"108","author":"Chiesa","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"2020121621270861200_B37","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.bbmt.2014.08.020","article-title":"Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial","volume":"20","author":"Burroughs","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2020121621270861200_B38","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1182\/bloodadvances.2020001748","article-title":"Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis [published correction in Blood Adv. 2020;4(16):3926]","volume":"4","author":"Felber","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2020121621270861200_B39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.hemonc.2019.12.003","article-title":"What is the impact of antithymocyte globulin pharmacokinetics on haploidentical hematopoietic stem cell transplantation?","volume":"13","author":"Oostenbrink","year":"2020","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"1","key":"2020121621270861200_B40","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","article-title":"Modern approaches to HLA-haploidentical blood or marrow transplantation [published correction in Nat Rev Clin Oncol 2016;13:132]","volume":"13","author":"Kanakry","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"2020121621270861200_B41","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.bbmt.2019.03.009","article-title":"Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for primary immunodeficiencies and inherited disorders in children","volume":"25","author":"Neven","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"2020121621270861200_B42","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood.2019001757","article-title":"Mismatched related vs matched unrelated donors in TCR\u03b1\u03b2\/CD19-depleted HSCT for primary immunodeficiencies","volume":"134","author":"Laberko","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2020121621270861200_B43","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.bbmt.2020.03.018","article-title":"HLA-haploidentical hematopoietic cell transplantation for treatment of nonmalignant diseases using nonmyeloablative conditioning and post-transplant cyclophosphamide","volume":"26","author":"Mallhi","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2020121621270861200_B44","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.bbmt.2019.05.036","article-title":"Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Zhao","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020121621270861200_B45","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.bbmt.2017.03.002","article-title":"The impact of splenectomy in myelofibrosis patients before allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Robin","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2020121621270861200_B46","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1182\/blood-2007-03-076679","article-title":"Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation","volume":"111","author":"Ozsahin","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2020121621270861200_B47","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s40262-019-00782-0","article-title":"Population pharmacokinetics of alemtuzumab (campath) in pediatric hematopoietic cell transplantation: towards individualized dosing to improve outcome","volume":"58","author":"Admiraal","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"2020121621270861200_B48","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(15)00045-9","article-title":"Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis","volume":"2","author":"Admiraal","year":"2015","journal-title":"Lancet Haematol"},{"key":"2020121621270861200_B49","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaci.2017.02.029","article-title":"Infective, inflammatory and autoimmune manifestations of disease in X-linked carriers of chronic granulomatous disease in the United Kingdom","volume":"140","author":"Battersby","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2020121621270861200_B50","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jaci.2017.04.035","article-title":"X-linked carriers of chronic granulomatous disease: Illness, lyonization, and stability","volume":"141","author":"Marciano","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2020121621270861200_B51","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jaci.2016.09.040","article-title":"Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome","volume":"139","author":"Nademi","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2020121621270861200_B52","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jaci.2016.01.045","article-title":"Hematopoietic stem cell transplantation for CTLA4 deficiency","volume":"138","author":"Slatter","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2020121621270861200_B53","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jaci.2017.04.023","article-title":"Treatment of severe forms of LPS-responsive beige-like anchor protein deficiency with allogeneic hematopoietic stem cell transplantation","volume":"141","author":"Seidel","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"2020121621270861200_B54","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2020121621270861200_B55","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/bmt.2016.113","article-title":"Can we agree on patient-reported outcome measures for assessing hematopoietic cell transplantation patients? A study from the CIBMTR and BMT CTN","volume":"51","author":"Shaw","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2020121621270861200_B56","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/j.jaci.2018.12.1013","article-title":"Combined liver and hematopoietic stem cell transplantation in patients with X-linked hyper-IgM syndrome","volume":"143","author":"Bucciol","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"2020121621270861200_B57","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1182\/blood-2017-04-777136","article-title":"Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult","volume":"130","author":"Morris","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2020121621270861200_B58","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1016\/S2352-3026(19)30021-3","article-title":"Lentiviral haemopoietic stem\/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1\/2 clinical study","volume":"6","author":"Ferrua","year":"2019","journal-title":"Lancet Haematol"},{"issue":"2","key":"2020121621270861200_B59","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41591-019-0735-5","article-title":"Lentiviral gene therapy for X-linked chronic granulomatous disease","volume":"26","author":"Kohn","year":"2020","journal-title":"Nat Med"},{"issue":"7109","key":"2020121621270861200_B60","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1038\/nature05219","article-title":"Gene therapy: X-SCID transgene leukaemogenicity","volume":"443","author":"Thrasher","year":"2006","journal-title":"Nature"},{"issue":"2","key":"2020121621270861200_B61","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease","volume":"16","author":"Stein","year":"2010","journal-title":"Nat Med"},{"issue":"97","key":"2020121621270861200_B62","doi-asserted-by":"crossref","first-page":"97ra79","DOI":"10.1126\/scitranslmed.3002715","article-title":"Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci Transl Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/649\/1795181\/hem2020000152c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/649\/1795181\/hem2020000152c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T18:18:42Z","timestamp":1608315522000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/649\/474361\/Allogeneic-hematopoietic-stem-cell-transplantation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020000152","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}